Acyclovir and hydrocortisone cream for the early treatment of recurrent cold sores

Carrie A. Sailer; Spotswood L. Spruance; Christopher M. Hull

doi:10.2147/VAAT.S7748

Acyclovir and hydrocortisone cream for the early treatment of recurrent cold sores

Carrie A. Sailer, Spotswood L. Spruance, Christopher M. Hull

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Current antiviral therapies for herpes simplex labialis primarily reduce healing time. Since the host immune response also plays a role in both controlling recurrent infection as well as producing clinical symptoms, new studies are showing efficacy using topical corticosteroids. This review will evaluate the safety and efficacy of 5% acyclovir-1% hydrocortisone cream (Xerese™[US], Xerclear^®[Europe]) for treatment of patients with herpes simplex labialis. A large, randomized, double-blind, placebo-controlled study recently demonstrated that treatment with 5% acyclovir-1% hydrocortisone cream significantly decreased the percentage of ulcerative lesions, reduced lesion healing time, and decreased mean lesion area compared with both topical acyclovir alone and vehicle

Original language	English (US)
Pages (from-to)	1-6
Number of pages	6
Journal	Virus Adaptation and Treatment
Volume	3
Issue number	1
DOIs	https://doi.org/10.2147/VAAT.S7748
State	Published - 2011
Externally published	Yes

Keywords

Acyclovir
HSV
Herpes labialis
Herpes simplex virus
Hydrocortisone
ME-609
Xerclear
Xerese

ASJC Scopus subject areas

Immunology
Virology
Infectious Diseases

Access to Document

10.2147/VAAT.S7748

Cite this

@article{5af6eb79e59848f991a8fd78de349b7e,

title = "Acyclovir and hydrocortisone cream for the early treatment of recurrent cold sores",

abstract = "Current antiviral therapies for herpes simplex labialis primarily reduce healing time. Since the host immune response also plays a role in both controlling recurrent infection as well as producing clinical symptoms, new studies are showing efficacy using topical corticosteroids. This review will evaluate the safety and efficacy of 5% acyclovir-1% hydrocortisone cream (Xerese{\texttrademark}[US], Xerclear{\textregistered}[Europe]) for treatment of patients with herpes simplex labialis. A large, randomized, double-blind, placebo-controlled study recently demonstrated that treatment with 5% acyclovir-1% hydrocortisone cream significantly decreased the percentage of ulcerative lesions, reduced lesion healing time, and decreased mean lesion area compared with both topical acyclovir alone and vehicle",

keywords = "Acyclovir, HSV, Herpes labialis, Herpes simplex virus, Hydrocortisone, ME-609, Xerclear, Xerese",

author = "Sailer, {Carrie A.} and Spruance, {Spotswood L.} and Hull, {Christopher M.}",

year = "2011",

doi = "10.2147/VAAT.S7748",

language = "English (US)",

volume = "3",

pages = "1--6",

journal = "Virus Adaptation and Treatment",

issn = "1179-1624",

publisher = "Dove Medical Press Ltd.",

number = "1",

}

TY - JOUR

T1 - Acyclovir and hydrocortisone cream for the early treatment of recurrent cold sores

AU - Sailer, Carrie A.

AU - Spruance, Spotswood L.

AU - Hull, Christopher M.

PY - 2011

Y1 - 2011

N2 - Current antiviral therapies for herpes simplex labialis primarily reduce healing time. Since the host immune response also plays a role in both controlling recurrent infection as well as producing clinical symptoms, new studies are showing efficacy using topical corticosteroids. This review will evaluate the safety and efficacy of 5% acyclovir-1% hydrocortisone cream (Xerese™[US], Xerclear®[Europe]) for treatment of patients with herpes simplex labialis. A large, randomized, double-blind, placebo-controlled study recently demonstrated that treatment with 5% acyclovir-1% hydrocortisone cream significantly decreased the percentage of ulcerative lesions, reduced lesion healing time, and decreased mean lesion area compared with both topical acyclovir alone and vehicle

AB - Current antiviral therapies for herpes simplex labialis primarily reduce healing time. Since the host immune response also plays a role in both controlling recurrent infection as well as producing clinical symptoms, new studies are showing efficacy using topical corticosteroids. This review will evaluate the safety and efficacy of 5% acyclovir-1% hydrocortisone cream (Xerese™[US], Xerclear®[Europe]) for treatment of patients with herpes simplex labialis. A large, randomized, double-blind, placebo-controlled study recently demonstrated that treatment with 5% acyclovir-1% hydrocortisone cream significantly decreased the percentage of ulcerative lesions, reduced lesion healing time, and decreased mean lesion area compared with both topical acyclovir alone and vehicle

KW - Acyclovir

KW - HSV

KW - Herpes labialis

KW - Herpes simplex virus

KW - Hydrocortisone

KW - ME-609

KW - Xerclear

KW - Xerese

UR - http://www.scopus.com/inward/record.url?scp=79952930419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952930419&partnerID=8YFLogxK

U2 - 10.2147/VAAT.S7748

DO - 10.2147/VAAT.S7748

M3 - Review article

AN - SCOPUS:79952930419

SN - 1179-1624

VL - 3

SP - 1

EP - 6

JO - Virus Adaptation and Treatment

JF - Virus Adaptation and Treatment

IS - 1

ER -

Acyclovir and hydrocortisone cream for the early treatment of recurrent cold sores

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this